蚓激酶治疗脑梗死

Lumbrokinase in treating cerebral infarction

目的 :观察蚓激酶治疗脑梗死的疗效。方法 :蚓激酶组 4 0例 (男性 2 2例 ,女性 18例 ,年龄 60a±s 12a) ,予蚓激酶 4 60mg ,po ,tid。对照组 4 0例 (男性 2 1例 ,女性 19例 ,年龄 60a± 10a) ,予右旋糖酐 4 0 ,50 0mL加川芎嗪 80mg ,iv ,drip ,qd。疗程均为 2 1d。结果 :蚓激酶组基本治愈率 38% ,总有效率 90 % ,对照组 15%及 73% ,差异有显著意义(P <0 .0 5) ;蚓激酶组治疗后血液流变学各指标及三酰甘油明显降低 ,梗死面积明显缩小 (均P <0 .0 1) ,与对照组比较差异有非常显著意义 (P <0 .0 1)。结论 :蚓激酶对脑梗死有较好疗效。

AIM: To observe the efficacy of lumbrokinase in treating cerebral infarction. METHODS: Lumbrokinase group of 40 patients (M 22, F 18; age 60 a± s 12 a) received lumbrokinase 460 mg, po , tid for 21 d. Control group of 40 patients (M 21, F 19; age 60 a±10 a) received ligustrazine 80 mg in dextran 40 injection 500 mL, iv drip, qd for 21 d. RESULTS: The basic curative rate in the lumbrokinase group (38%) was higher than that in the control group (15%), the total effective rate in the lumbrokinase group (90%) was superior to that in the control group (73%). There was a significant difference between the two groups ( P <0.05). Lumbrokinase group's hemorheologic parameters, triglyceride and infarction area dropped remarkably ( P <0.01). There was a very significant difference between the tow groups ( P <0.01). CONCLUSION: Lumbrokinase has a better effect in treatment of cerebral infarction.